What's in Enanta Pharmaceuticals, Inc's pipeline?

Enanta Pharmaceuticals, Inc has 12 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 4 in Phase 2, 7 in Phase 1.

Which companies overlap with Enanta Pharmaceuticals, Inc's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/enanta-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Enanta Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enanta Pharmaceuticals, Inc pipeline: 1 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 4 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Carbamazepin	Carbamazepin	marketed		Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	Neuroscience

Therapeutic area mix

Neuroscience · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Enanta Pharmaceuticals, Inc:

Cite this brief

Drug Landscape (2026). Enanta Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/enanta-pharmaceuticals-inc. Accessed 2026-05-16.